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ABSTRACT Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are
limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the
inflammatory, infective and molecular drivers of disease progression are not fully understood, making the
development of novel treatments challenging. Understanding the role bacteria play in disease progression
has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing.
The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial
communities dominated by Pseudomonas, Haemophilus and Streptococcus, while exhibiting intraindividual
stability and large interindividual variability. Pseudomonas- and Haemophilus-dominated microbiomes
have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are
limited in size and do not fully represent all clinically observed disease subtypes. Further research is
required to understand the microbiomes role in bronchiectasis disease progression. This review discusses
recent developments and future perspectives on the lung microbiome in bronchiectasis.
Introduction
Bronchiectasis is a common chronic lung disease with heterogeneous clinical features and outcomes [1, 2].
The prevalence of bronchiectasis in Europe and North America ranges from 67 to 566 per 100000
inhabitants, and is as high as a 1200 per 100000 in China, making it a serious and growing economic
health burden [3–5].
The cause of disease progression is hypothesised to be the result of a complex interaction between chronic
infection, inflammation and impaired mucociliary clearance, which leads to structural changes in the
lungs, allowing further infections to develop [6–9]. Each of these individual components interacts with the
others, allowing the disease to progress.
Disease-associated exacerbations have a major effect on patient healthcare costs as well as quality of life
due to increased lung damage and mortality risk [10–13]. Microorganisms such as Pseudomonas
aeruginosa and, to a lesser extent, other Gram-negative and Gram-positive microorganisms identified in
culture, have been linked to disease progression, poor clinical outcomes in bronchiectasis and driving airway
neutrophil-mediated inflammation [14–19]. For this reason, long-term antibiotic therapy is one of the
mainstays of treatment for the management of bronchiectasis with frequent exacerbations [10, 13, 20, 21].
The development of accessible molecular methods for studying lung microbial communities is changing our
understanding of airway microbiology [22]. In turn, this is affecting our understanding of the contribution of
infection to the pathophysiology of bronchiectasis. The microbiome has the potential to provide valuable
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information regarding disease phenotype/endotype, treatment responses and targets for future therapy
[23–25]. In this review, we discuss the potential role of the microbiome in bronchiectasis.
Healthy lung microbiome
The microbiome is defined as the combined genetic material of all microorganisms in an environment [26].
This is distinct from the microbiota, which is defined as the ecological community of commensal,
symbiotic and pathogenic microorganisms found in a specific niche. In practice, these terms are often used
interchangeably. Central to the field of microbiome research is an understanding that the human body is
host to a vast array of different microorganisms that interact with the host and each other to produce
important effects of health and disease [27, 28]. Traditionally, clinical practice has used culture to
investigate bacteria in the lungs, but this selects for growth of known, predominantly aerobic, respiratory
pathogens [29]. Molecular-based methods offer an alternative to culture and include 16S ribosomal (r)
RNA sequencing and metagenomic sequencing [29]. These methods aim to capture genetic information
from all bacteria, or in the case of metagenomics, all DNA sequences, present in a sample. The rapid
development of this field has required clinical researchers to rapidly adopt a new language for describing
lung microbial communities and their impact on disease. Current general microbiome terminology is
described in table 1. Common phyla identified by 16S rRNA sequencing in the healthy lung include
Proteobacteria, Firmicutes and Bacteroidetes, while at the genus level Streptococcus, Prevotella and
Veillonella predominate, with lesser contributions from Haemophilus and Neisseria [29–31]. The healthy
lung microbiome is believed to be transient and depends on three factors, as follows. 1) Microbes moving
into the airways from inhalation, microaspiration and direct mucosal dispersion; 2) the speed at which the
mucocilliary system and innate immune system remove microbes; and 3) whether conditions in certain
regions of the lung are able to favour microbial growth [32]. Lung disease alters the structure of the lung
and changes regional growth conditions. The modifiers of the lung microbiome are illustrated in figure 1.
In bronchiectasis the airways become widened, leading to a failure of mucociliary clearance allowing
bacterial adherence, increased bacterial loads and the development of chronic infection [8].
Bronchiectasis microbiome versus culture
The field of microbiome research in bronchiectasis is less advanced than the field of other respiratory
diseases such as cystic fibrosis and chronic obstructive pulmonary disease (COPD), with fewer published
studies [33–36]. Nevertheless, evidence to date suggests remarkable consistency in findings across
supposedly distinct disease entities [37–40]. The first group of published bronchiectasis microbiome
studies have supported the findings of culture-based studies, identifying genera associated with infection
such as Haemophilus, Streptococcus and Pseudomonas, while also providing evidence of bacterial
pathogens in culture-negative patients [41–43]. The microbiology of bronchiectasis and a representative
microbiome profile for the bronchiectasis population (hypothetical data based on published work) are
shown in figure 2 [44–46]. Overall, bronchiectasis microbiome studies support the findings reported by
culture in terms of dominant organisms. Microbiome studies have shown the bronchiectasis microbiome is
TABLE 1 Commonly used terminology in microbiome studies
Microbiota The whole collection of microorganisms within a specific location (e.g. the lung), includes bacteria, fungi and viruses
Microbiome The genetic information and inferred physiochemical properties of the gene products of the microbiota. In most articles the
term is used to mean the taxonomic classification of bacteria present in a sample and is used as such in this review
Bacteriome The genetic information and inferred physiochemical properties of the gene products of the bacteria present in a specific
location
Mycobiome The genetic information and inferred physiochemical properties of the gene products of the fungi present in a specific location
Virome The genetic information and inferred physiochemical properties of the gene products of the viruses present in a specific location
Metagenomics Shotgun random sequencing of total DNA in a sample, including DNA from host and microbe origin, which is analysed,
organised and identified using sequence databases and computational tools
16S rRNA gene Component of the 30S small subunit of prokaryotic ribosomes. It is used in molecular studies owing to its extremely slow
rate of evolution and the presence of both variable and constant regions
OTUs Clusters of similar 16S rRNA gene sequences. Each OTU represents a taxonomic unit of a bacteria family or genus
depending on the sequence similarity threshold. Identification to the species level is not usually possible
α-diversity α-diversity is a measure of how diverse a sample is based on how many species there are (richness) and how abundant each
species is (evenness) within that sample
β-diversity β-diversity is used to show how different samples are from each other, based on differences in bacterial presence,
abundance or a phylogenetic tree
rRNA: ribosomal RNA; OTUs: operational taxonomic units.
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complex, contains multiple bacterial genera and is highly individual [46, 47]. A recent longitudinal study
by WOO et al. [48] followed 29 bronchiectasis patients for up to 16 years and demonstrated remarkable
stability of the microbiome over many years of follow-up. The microbiomes of Pseudomonas- and
Haemophilus-dominated patients were widely divergent and patients maintained similar profiles over time
despite antibiotic treatments [48]. This is consistent with what has been seen with culture, where chronic
infection with P. aeruginosa or H. influenzae often persists over many years regardless of therapy [49]. Few
studies have examined the microbiome during exacerbations, but these are reviewed later.
A minority of studies have used quantitative (q) real-time PCR to determine bacterial load, as 16S rRNA
sequencing cannot quantify the bacteria present. The reported bacterial load in bronchiectasis patients
ranged from 104 to 1010 CFU·mL−1 when total viable counts and qPCR have been performed [47, 50].
Does the microbiome play a role in exacerbations and affect disease severity?
Exacerbations in bronchiectasis can be caused by a range of bacteria, viruses and environmental factors;
making it hard to determine the role of the microbiome in exacerbations [51]. It is known from culture
studies that bacterial load is important in lung inflammation and treatment response [14, 52]. Microbiome
changes during exacerbation are heterogeneous. In one study, some patients exhibited minimal changes,
while in other patients marked changes in the relative abundance of different taxa occurred [47]. The
overall conclusion by COX et al. [47] was that there was no statistically significant increase in bacterial load
during exacerbation compared to baseline, and there were no consistent changes in diversity or other
microbiome parameters during exacerbation. This does not mean that the microbiome is not involved in
exacerbations of bronchiectasis patients, but suggests that there are some, as yet identified, subtypes of
exacerbations associated with diverse changes [47]. Furthermore, there was no significant difference in
bacterial load between baseline, exacerbation, treatment and recovery samples. In a pattern similar to what
has been seen in cystic fibrosis, measures of α- and β-diversity across all patients in this study are
associated with measures of clinical severity, including lung function [35, 47]. Several studies suggest that
severe bronchiectasis is reduced with lower diversity of the microbiome measured by composite indices
Microbial immigration
Microaspiration, mucosal
dispersion and environmental 
inhalation
Increased immigration
Patient factors
Upper airway disease
Impaired swallow
Gastro-oesophageal reflux
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FIGURE 1 Illustration of the factors modifying the healthy and diseased lung microbiome. The arrows illustrate the immigration of bacteria to the
lungs and the balanced removal of bacteria by mucociliary clearance and immune clearance. Multiple factors have been described that increase
immigration of bacteria and decrease clearance, leading to dysbiosis. The list is not intended to be comprehensive. NTM: nontuberculous
mycobacteria.
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such as the Shannon diversity index [42]. WOO et al. [48] demonstrated in their small study (n=29) that
very low diversity values were associated with more rapid lung function decline.
In the BLESS (Bronchiectasis and Low-dose Erythromycin Study) study, low-dose erythromycin (400 mg,
twice daily) was given to stable bronchiectasis patients for 48 weeks in a double-blind, placebo-controlled,
randomised controlled trial [53]. The overall study demonstrated a significant reduction in exacerbations
in the erythromycin-treated patients compared to placebo. When the microbiomes of the included patients
were examined, it was shown that patients with a Haemophilus-dominated microbiome had fewer
exacerbations, while patients with a Pseudomonas- or Veillonella-dominated microbiome profile had an
increased frequency of exacerbations overall (in both the active agent- and placebo-treated patients) [54].
Patients with P. aeruginosa infections are known to have poorer clinical outcomes, including more
frequent exacerbations, decline in lung function, higher requirement for antibiotic therapy and greater
sputum production [12, 55–58]. In the BLESS study, Pseudomonas- or Haemophilus-dominated
microbiomes were associated with significantly reduced lung function compared to other microbiome
profiles (forced expiratory volume in 1 s 56.8%, 69.9% and 73.1%, respectively) [54].
Using the BLESS cohort, the microbiome was compared to measures of inflammation including sputum
interleukin (IL)-1β, IL-8, matrix metalloproteinases (MMPs) and serum C-reactive protein (CRP) [50].
Genus richness was negatively associated with sputum IL-1β and IL-8, while Pseudomonas- or
Haemophilus-dominated microbiomes were associated with increased levels of serum CRP, sputum IL-1β
and IL-8 [50, 54]. Stratifying patients based on dominant microbiome showed that H. influenza-dominated
microbiomes had significantly higher levels of MMP2 (p<0.01) and MMP8 (p<0.03) compared to those
a)
d) Healthy microbiota
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FIGURE 2 The microbiology of bronchiectasis. a) Culture-based microbiology results from a European cohort study [44]; b) culture-based
microbiology results from the US Bronchiectasis Registry [43]; c) a representative microbiome profile for the bronchiectasis population
(hypothetical data based on published work) [45] (low-abundance genera (<1%) such as Leptotrichia are not shown); d) simplified concept of
microbiota dysbiosis and loss of diversity in the bronchiectasis lung. NTM: nontuberculous mycobacteria.
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with a Pseudomonas-dominated microbiome [50]. It is important to consider that this dataset (86 patients)
is relatively small, with modest numbers of Haemophilus- (31 patients) or Pseudomonas- (22 patients)
dominated microbiomes. Larger studies are required to confirm these findings.
Antibiotics and the bronchiectasis microbiome
The findings from the BLESS study are cross-sectional and do not discuss the effects of the antibiotic
treatment itself. In a post hoc analysis of the BLESS study, a significant change in the microbiome was
observed in the erythromycin group compared to placebo with a significant increase in microbiome
richness [46]. The response was different depending on the infecting organism at baseline. Erythromycin
did not result in significant changes in microbiome composition evaluated by the Bray–Curtis dissimilarity
index in patients with a Pseudomonas-dominated microbiome, but significantly reduced the rate of
pulmonary exacerbations compared to placebo in this group [42]. Erythromycin reduced the relative
abundance of Haemophilus in patients with non-Pseudomonas-dominated microbiomes and promoted
displacement with more macrolide-tolerant pathogens, but did not significantly reduce the rate of
pulmonary exacerbations. Furthermore, an increased relative abundance of Pseudomonas was observed in
these patients [42]. The clinical significance of this finding is uncertain, as macrolide therapy is highly
beneficial in the treatment of bronchiectasis, but these data raise a concern that it may promote infection
with Pseudomonas, which has a worse outcome over the longer term [59]. The impact of inhaled
antibiotics on the microbiome has not been investigated. Ideally, the impact on the lung microbiome by all
the commonly used antibiotics to treat respiratory infections in bronchiectasis needs to be investigated [60].
The role of fungi, viruses and nontuberculous mycobacteria
The role of fungi, viruses and nontuberculous mycobacteria (NTMs) in bronchiectasis are less well
defined, but are likely to be significant in bronchiectasis [28, 61]. The CAMEB (Cohort of Asian and
Matched European Bronchiectasis) study was the first to investigate the lung mycobiome in a cohort of
238 Asian and matched European bronchiectasis patients. Common genera observed in the bronchiectasis
mycobiome were Aspergillus, Cryptococcus and Clavispora [62]. Geographical variation was observed, with
two different Aspergillus species detected using qPCR. Aspergillus fumigatus was detected as the
predominant species in patients from Singapore/Kuala Lumpur and Aspergillus terreus was predominant in
patients from Dundee. Further investigation of the lung mycobiome needs to be performed.
Several viruses, including influenza A and B, adenovirus, parainfluenza, rhinovirus and human
T-lymphotropic virus-1 have been identified in bronchiectasis patients [63–66]. MITCHELL et al. [67]
conducted two studies using PCR, including 47 and 27 patients, and identified viruses in 39% and 59% of
bronchiectasis patients, respectively, during stable state. This suggests a remarkably high frequency of
viruses even during stable disease. However, extensive virome studies have not been performed. Further
studies need to investigate whether viruses are a cause or consequence of exacerbations. It has been
suggested that viruses play a role in bronchiectasis exacerbations even when bacterial load and diversity are
stable [63].
The role of NTMs in the bronchiectasis microbiome is less understood. Common NTMs reported include
members of the Mycobacterium avium complex and Mycobacterium abscessus complex [68–70]. It is
possible that NTMs act as a trigger for bronchiectasis as hypothesised with Mycobacterium avium
subspecies paratuberculosis and Crohn’s disease [71]. The role of fungi, NTM and viruses are currently
less studied, in part due to limitations of the methods used. These organisms, particularly fungi and
Mycobacteria, present difficulties related to DNA extraction, as well as the lack of agreement on
appropriate methods for sequencing and databases to identify micro-organisms. The widely used 16S
rRNA sequencing methods used for microbiome studies do not identify Mycobacteria accurately [72].
SULAIMAN et al. [72] studied a cohort of patients with NTM infection using 16S rRNA sequencing, and
despite these patients being culture-positive for NTM, few mycobacteria were identified by sequencing.
There was an association between oral commensals and inflammatory responses, suggesting a modulating
effect of other microbiota in NTM lung disease.
What is still missing?
To date, microbiome data have not led to changes in clinical practice, but it is important to investigate
associations between the microbiome and clinical presentation to help guide treatment. Previous
bronchiectasis microbiome studies have been limited by the number of patients tested (<150 patients) and
the duration of patient follow-up (<1 year). Future microbiome studies need to have an extended follow-up
period and include larger numbers of patients to capture the disease heterogeneity during stability and at
exacerbation. Ideally, methodology in future microbiome studies needs to be standardised. Previous studies
have shown this as there is variation in methodology from one study to the next, as shown in table 2.
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TABLE 2 Summary of bronchiectasis microbiome studies
First author,
[ref.]
Year Sample
size n
Sample
type
Patient characteristics DNA extraction 16S
region
Sequencing method Data analysis Taxa found
BYUN [41] 2017 14 Sputum,
BAL
Stable and exacerbated MG Blood Genomic DNA
Extraction SV kit (MGmed, Seoul,
Republic of Korea)
V2,4,8
V3,6–
7,9
Ion 318 v2 chip, Ion
PGM Sequencing 400
kit (Life Technologies,
Carlsbad, CA, USA)
QIIME [37] and R
packages
Haemophilus, Pseudomonas,
Moraxella, Klebsiella, Prevotella and
Veillonella
COX [47] 2017 76 Sputum Stable and exacerbated
samples
FastDNA Spin Kit for Soil (MP
Biomedicals, Santa Ana, CA,
USA)
V3-V5 Roche 454 FLX
sequencer (Basel,
Switzerland)
QIIME and R
packages
Haemophilus, Pseudomonas and
Staphylococcus
MAUGHAN [73] 2012 31 Lung
tissue
Surgical resection/lung
transplantation
Direct PCR DNA Extraction
System (Viagen Biotech, Los
Angeles, CA, USA)
V1-V4 Applied Biosystems
(Foster City, CA, USA)
3130XL sequencer
QIIME Pseudomonas, Stenotrophomonas,
Staphylococcus, Burkholderia and
Haemophilus
PURCELL [74] 2014 70 Sputum 20 exacerbated, 50
non-exacerbated
MoBio Ultraclean Microbial DNA
isolation kit (MoBio, CA, USA)
V3 Pyrosequencing QIIME Pasteurellaceae, Streptococceae,
Pseudomonadaceae,
Prevotellaceae, Veillonellaceae and
Actinomycetaceae
ROGERS
(BLESS)
[42]
2013 41 Sputum,
BAL
Clinically stable patients
with at least two infective
exacerbations in the
previous 12 months
Laboratory-specific protocol
including a bead-beating step
and a phenol/chloroform
precipitation
V1-V3 Pyrosequencing Custom C# software
in MicrosoftH.NET
environment
Pseudomonas, Haemophilus,
Streptococcus, Prevotella, Veillonella
and Neisseria
ROGERS
(BLESS)
[54]
2014 96 Sputum Patients required to be
clinically stable, not
receiving systemic
corticosteroids and
macrolide-naive
Laboratory-specific protocol
including a bead-beating step
and a phenol/chloroform
precipitation
V1-V3 Pyrosequencing Custom C# software
in MicrosoftH.NET
environment
Haemophilus, Pseudomonas,
Veillonella and Streptococcus
ROGERS
(BLESS)
[46]
2014 96 Sputum As above As above V1-V3 Tag-encoded FLX
amplicon
pyrosequencing
(bTEFAP)
QIIME N/A
Continued
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TABLE 2 Continued
First author,
[ref.]
Year Sample
size n
Sample
type
Patient characteristics DNA extraction 16S
region
Sequencing method Data analysis Taxa found
ROGERS
(BLESS)
[75]
2015 60 Sputum Stable As above V1-V3 Pyrosequencing PAST
(palaeontological
statistics)
Patients stratified as Haemophilus-
or Pseudomonas-dominated
microbiomes
TAYLOR
(BLESS)
[50]
2015 86 Sputum Patients required to be
clinically stable, not
receiving systemic
corticosteroids and
macrolide naive
Laboratory-specific protocol
including a bead-beating step
and a phenol/chloroform
precipitation
V1-V3 Bacterial tag-
endocoded FLX
amplicon
pyrosequencing
Custom C# software
in MicrosoftH.NET
environment
Patients stratified as Haemophilus-
or Pseudomonas- or
other-dominated microbiomes
TUNNEY [43] 2013 29 Sputum Stable and exacerbated
(pre- and post-antibiotics)
FastDNA Spin Kit MP
Biomedicals, Santa Ana, CA,
USA) and OneStep™ PCR
Inhibitor Removal Kit (Zymo
Research, Irvine, CA, USA)
V1-V3 Pyrosequencing QIIME Haemophilus, Streptococcus,
Pseudomonas and Achromobacter
VAN DER GAST
(BLESS)
[76]
2014 19
children
38 adults
Sputum,
BAL
Stable Laboratory-specific protocol
including a bead-beating step
and a phenol/chloroform
precipitation
V1-V3 Tag-encoded
FLX-titanium
pyrosequencing
Mothur, BLASTn Haemophilus, Pseudomonas,
Veillonella, Streptococcus and
Prevotella
BAL: bronchoalveolar lavage; QIIME: Quantitative Insights Into Microbial Ecology.
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It is unlikely that microbiome sequencing in its current form will ever make it into clinical practice; it is
labour-intensive, time-consuming and requires specialised bioinformatics analysis. Third-generation
sequencing techniques such as the MinION (Oxford Nanopore Technologies) and single-molecule
real-time sequencing (PacBio) have the potential to be used in clinical practice. The MinION has been
used previously for microbiological investigation of lower respiratory tract infections and in the INHALE
study (UK) for rapidly identifying the cause of hospital-acquired and ventilator-associated pneumonia
[77, 78]. To be used in clinical practice any molecular method would need to be a “sample in/answer out”
approach, something not currently possible with microbiome sequencing. Quantifying and identifying
bacteria does not begin to address the complexity of host–microbiome interactions and, in addition,
emerging techniques are starting to address bacterial metabolism, gene expression, resistance and host
response. This is a rapidly developing field and these techniques will shortly be applied in bronchiectasis.
Conclusion
Compared to other lung diseases such as COPD and cystic fibrosis, the microbiome is far less understood
in bronchiectasis; the majority of data have come from the BLESS trial [53, 79, 80]. In the next 5 years, the
Bronchiectasis Research Involving Databases, Genomics and Endotyping (BRIDGE) study (NCT03791086)
will sequence 1000 bronchiectasis patient samples from across Europe with the aim to determine
molecular endotypes of bronchiectasis during stable disease. While this will provide valuable data, more
research is needed to increase our understanding of the microbiome in heterogeneous populations of
patients, both when stable and exacerbated and in response to different treatments. These data should be
used to guide more personalised treatment approaches or to identify cohorts of patients more likely to
respond to particular treatments within a clinical trial.
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